TY - T1的特点和哮喘COVID-19肺炎患者需要住院治疗的结果JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01875 -2020欧元六世- 56 - 5 SP - 2001875 AU Beurnier安东尼盟——Jutant Etienne-Marie盟——Jevnikar Mitja盟——仿羔皮呢,Athenais AU - Pichon,杰雷米非盟- Preda马里亚纳非盟-弗兰克,玛丽AU -劳伦,杰里米非盟-理查德,基督教非盟-莫内,泽维尔盟——Duranteau雅克盟——Harrois士盟——Chaumais Marie-Camille盟——Bellin Marie-France AU -诺尔,尼古拉斯盟——Bulifon苏菲AU -洁,泽维尔盟——家长,佛罗伦萨盟——Seferian安德烈•AU - Savale Laurent盟——Sitbon病毒性呼吸道感染是哮喘加重的主要原因。当哮喘患者表现出由严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染引起的严重肺炎时，其病情加重的易感性尚不清楚。本研究的目的是调查2020年春季法国巴黎疫情期间需要住院治疗的哮喘型2019冠状病毒病(COVID-19)肺炎患者的特征和结局。方法2020年3月15日至4月15日在法国巴黎-萨克莱大学Bicêtre医院进行前瞻性队列随访。所有报告有哮喘史的SARS-CoV-2感染住院患者均纳入研究。结果768例住院患者中有37例(4.8%)有哮喘病史，其中85%的患者曾经肺科医生确诊。这些哮喘患者主要为女性(70%)和非吸烟者(85%)，中位年龄54岁(四分位差(IQR) 42-67岁)。他们都没有哮喘发作。22例(59%)有主要共病，31例(84%)体重指数≥25 kg·m - 2。 The most common comorbidities were obesity (36%), hypertension (27%) and diabetes (19%). All patients had a confirmed diagnosis of COVID-19 pneumonia on computed tomography of the chest. Eosinopenia was a typical biological feature with a median count of 0 cells·mm−3 (IQR 0–0 cells·mm−3). 11 patients (30%) were admitted into the intensive care unit, with three deaths (8.1%) occurring in the context of comorbidities.Conclusion Asthma patients were not overrepresented among those with severe pneumonia due to SARS-CoV-2 infection who required hospitalisation. The worst outcomes were observed mainly in patients with major comorbidities.Asthmatic patients were not overrepresented among those with severe pneumonia due to SARS-CoV-2 infection who required hospitalisation. None presented with an asthma exacerbation. Worst outcomes were observed mainly in patients with major comorbidities. https://bit.ly/303djG6 ER -